These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Herpes simplex virus vaccine studies: from past to present].
    Author: Us D.
    Journal: Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702.
    Abstract:
    The dramatical increase in the prevalence of Herpes simplex virus (HSV) infections and the significant physical and psychosocial morbidity of HSV type 2 infections, generate the need for an efficacious HSV vaccine. The most important properties of HSVs that should be targeted for a successful vaccine are neuronal invasion, latency and reactivation in spite of specific host immune responses. The major expectation for an ideal HSV vaccine candidate is to induce sterilizing immunity, which must be effective at all portals of HSV entry; to prevent or reduce the symptomatic disease and to eliminate or at least to limit the asymptomatic viral shedding. The first vaccine studies have began in the 1920s and in the intervening eight decades there have been many attempts to develop an effective one. Although encouraging findings came from experiments in various animal models, human studies have been disappointing, unfortunately. The vaccine strategies that have undergone clinical evaluation until today included autoinoculation of live HSV, whole inactivated vaccines, attenuated live virus vaccines, modified live virus subunit vaccines, cell culture-derived subunit vaccines, recombinant subunit (glycoprotein) vaccines, DISC (Disabled Infectious Single Cycle) virus vaccines, viral vectors and naked DNA vaccines. In most of the clinical studies the failure of HSV vaccines in spite of inducing very high levels of specific neutralizing antibodies have emphasized that cell-mediated immune response, especially Thl type immunity is important in preventing both primary disease and recurrences with HSV, rather than humoral response. The most hopeful result was obtained with HSV-2 gD and alum/MPL vaccine in clinical studies. This vaccine was found 74% effective in preventing genital disease in HSV seronegative women but was not effective in men or seropositive women. In recent years it is possible to genetically engineer HSV to produce a vaccine strain that is protective without causing human disease. An example for this strategy was the development of a live attenuated vaccine from which neurovirulence gene (gamma1 34.5) has been removed. Another promising one was the replication-defective DISC virus HSV vaccine which is derived from a virus with an essential gene (e.g. gH gene) deleted, so the replication has been limited only to a single cycle. As a result, intensive HSV vaccine trials are currently underway, although all the previous attempts to produce an effective vaccine for the prophylaxis and immunotherapy against HSV have been largely unsuccessful. In this review the history of HSV vaccine development together with the preclinical and clinical studies from past to present has been summarized and recent progress for an effective HSV vaccine together with the further improvements required for an immunogenic vaccine have been discussed.
    [Abstract] [Full Text] [Related] [New Search]